Inhaled beta 2-adrenoceptor agonists in asthma: help or hindrance?
about
Stepping down the dose of inhaled corticosteroids for adults with asthmaRegular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse eventsRegular treatment with formoterol for chronic asthma: serious adverse eventsRegular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse eventsRegular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse eventsRegular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse eventsRegular treatment with formoterol for chronic asthma: serious adverse eventsRegular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse eventsRegular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse eventsRegular treatment with salmeterol for chronic asthma: serious adverse eventsRisk of non-fatal cardiac failure and ischaemic heart disease with long acting beta 2 agonistsIncreased risk of sudden cardiac arrest in obstructive pulmonary disease: a case-control studyRelaxation and music therapies for asthma among patients prestabilized on asthma medication.Sex differences in hypokalaemic and electrocardiographic effects of inhaled terbutaline.Studies on the bronchodilator, tremorogenic, cardiovascular and hypokalaemic effects of fenoterol dry powder in asthma.Stepping down the dose of inhaled corticosteroids for adults with asthma.Salmeterol: a novel, long-acting beta 2-agonist.Effects of catecholamines on plasma potassium: the role of alpha- and beta-adrenoceptors.Sympathomimetic enantiomers and asthma.Characterization of monolithic matrix patch system containing tulobuterol.Antibronchospasmic, tachycardiac, and hypokalaemic effects of L-isoproterenol in guinea-pigs.The pharmacodynamics, pharmacokinetics, safety and tolerability of inhaled fluticasone furoate and vilanterol administered alone or simultaneously as fluticasone furoate/vilanterol.
P2860
Q24188187-0D286994-5D35-446C-90B2-120CEF9D8558Q24199079-44B04B76-C222-4AC6-BD81-F12120883705Q24200353-31253064-E7C6-4894-98BF-E8FC15C6073DQ24201048-1B17AD5D-E2DB-47F1-96B3-652681EC5BABQ24202005-AA220791-A59E-4A1C-BA6F-A25A2AA55A54Q24240282-9659219B-9E6C-4FB0-87EC-B65803ECB814Q24241250-9C11CEC3-A7F9-472D-9B01-DF70982ECD0BQ24241453-67E84275-2074-4395-AFFE-BBE719ECFD50Q24241740-94B362A0-79FE-40B1-B7E8-CDB5D93EC5CFQ24241960-2263CC98-4036-404C-BB81-153940CA80D9Q28369181-579418B3-949E-4302-8A7E-B3726DBD467BQ28533685-E7A36431-0AB2-4136-8FD1-8AA476F6D548Q30421274-DCDA5C3B-140B-4F2D-8D5D-9D3905B7EBB3Q33604623-9A3A10DB-6CE7-4883-B162-DDF49E9BFFC3Q34345856-9E0AA5C9-4919-4DA7-938E-4CE08907A4F0Q38986452-F3F5D33D-0A11-4656-8C40-E4EBD7DADF3CQ40620716-0AF2DCF9-88C0-489E-811C-429B61D5D253Q40854359-FCD80FE8-B304-4C0A-B774-A7D0E05448EAQ41719837-14DF67B5-F549-4E8A-A78B-3BB420D8DA28Q46371990-F3636667-29BD-4055-9104-BB49585A3A67Q46557532-32D323F6-9E50-4DC6-A7D8-9050FC36DBB0Q51671642-97F87E2E-5C8D-4478-828C-06F93923DF55
P2860
Inhaled beta 2-adrenoceptor agonists in asthma: help or hindrance?
description
1992 nî lūn-bûn
@nan
1992 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Inhaled beta 2-adrenoceptor agonists in asthma: help or hindrance?
@ast
Inhaled beta 2-adrenoceptor agonists in asthma: help or hindrance?
@en
type
label
Inhaled beta 2-adrenoceptor agonists in asthma: help or hindrance?
@ast
Inhaled beta 2-adrenoceptor agonists in asthma: help or hindrance?
@en
prefLabel
Inhaled beta 2-adrenoceptor agonists in asthma: help or hindrance?
@ast
Inhaled beta 2-adrenoceptor agonists in asthma: help or hindrance?
@en
P2860
P1476
Inhaled beta 2-adrenoceptor agonists in asthma: help or hindrance?
@en
P2093
Lipworth BJ
McDevitt DG
P2860
P304
P356
10.1111/J.1365-2125.1992.TB04014.X
P407
P577
1992-02-01T00:00:00Z